Oncolytics Biotech's (ONCY) Buy Rating Reiterated at HC Wainwright

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $5.00 price objective on the stock. HC Wainwright also issued estimates for Oncolytics Biotech's FY2027 earnings at ($0.08) EPS, FY2028 earnings at $0.39 EPS and FY2029 earnings at $0.73 EPS.

Several other research firms have also issued reports on ONCY. Royal Bank of Canada cut their price target on Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating for the company in a report on Monday. Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a report on Thursday, November 14th. Finally, Leede Financial lowered Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a report on Wednesday, November 13th. Three research analysts have rated the stock with a buy rating, According to MarketBeat.com, Oncolytics Biotech currently has an average rating of "Buy" and a consensus target price of $4.00.

Oncolytics Biotech Stock Up 0.3 %

NASDAQ:ONCY traded up $0.00 during mid-day trading on Monday, hitting $0.63. 118,147 shares of the company traded hands, compared to its average volume of 1,288,895. The stock's fifty day moving average price is $0.76 and its 200-day moving average price is $0.92. Oncolytics Biotech has a one year low of $0.58 and a one year high of $1.53. The firm has a market cap of $53.44 million, a price-to-earnings ratio of -2.31 and a beta of 1.18.

Remove Ads

Hedge Funds Weigh In On Oncolytics Biotech

Hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in Oncolytics Biotech during the fourth quarter valued at approximately $90,000. National Bank of Canada FI boosted its stake in Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock valued at $60,000 after buying an additional 42,955 shares during the last quarter. Vantage Point Financial LLC bought a new position in Oncolytics Biotech during the fourth quarter valued at approximately $27,000. International Assets Investment Management LLC boosted its stake in Oncolytics Biotech by 15.0% during the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company's stock valued at $186,000 after buying an additional 26,069 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock valued at $61,000 after buying an additional 24,997 shares during the last quarter. Institutional investors own 6.82% of the company's stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.